By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. The U.S. Food and Drug Administration’s decision on mitapivat, a pill for sickle cell disease, is due November 1, 2026. Mitapivat is not a cure. In Phase 3 trials, however, it raised hemoglobin levels — and for people living crisis to crisis,
Mitapivat Decision Due November 1: A Pill, Not a Cure — But a Step Forward Read More »
By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. A study from Conakry, Guinea, has found hydroxyurea linked to fewer sickle cell crises — welcome evidence from a region where sickle cell disease affects so many families, and where access to treatment is often limited. The study followed 102 patients and
Hydroxyurea Linked to Fewer Crises in Guinea: What a 102-Patient Study Shows Read More »
By Tosin Ola, RN, BSN, MBA-HCM, Founder & President, Sickle Cell Warriors Foundation. Aisha has become the first patient in the United Kingdom to complete gene-editing therapy for sickle cell disease — and is now living without sickle cell crises. This milestone, reported by Manchester University NHS Foundation Trust, matters far beyond one hospital. For
A First in the UK: A Patient Completes Gene-Editing Therapy for Sickle Cell Disease Read More »
Sickle Cell Warriors Inc. Presents The Impact of Sickle Cell Disease on Your Hearing and Balance -The association between hearing loss/dizziness and SCD -Recent national changes to hearing health care for those with SCD -Treatment options and next steps -Research update đź“… Thursday, March 19 đź•’ 3:00 PM Pacific | 6:00 PM Eastern đź’» Virtual
The Impact of Sickle Cell Disease on your Hearing and Balance Read More »
Learn more about the Hibiscus Study Clinical trials are critical to finding new or improved treatments for diseases. By participating in a clinical trial for sickle cell disease (SCD), you could help researchers better understand the disease or find new treatments that can be given to SCD patients in the future. About the Hibiscus Study™
Learn more about the Hibiscus Study Read More »
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting – Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion – – Sickle cell disease: All seven patients were free of vaso-occlusive crises after
New data for Vertex and CRISPR Therapeutics Read More »
Multiple myeloma is a relatively rare cancer that develops in the bone marrow. As the cancerous plasma cells accumulate in the marrow, they crowd out other healthy blood cells. Unfortunately, the symptoms including bone pain, mental fogginess, excessive thirst may develop slowly over time and don’t usually appear until the disease reaches an advanced stage. In
Are You at Risk for Multiple Myeloma? Read More »
Depression and Kids with SCA Older age and higher education level showed increased scores. “A new study from Nigeria found that depression in young patients with sickle cell disease (SCD) was linked with increasing age and education level.” There is a new Nigerian study with teens and children who have sickle cell anemia (SCA). The
Pediatric Depression in SC Read More »
The COVID pandemic has impacted the globe. It has also brought to the forefront the fact that people of color have more enormous challenges to receiving health care. These glaring disparities in health care are the most significant cause of death in black and brown people. Despite the Institute of Medicine’s report in 2003 stating that minorities
Black Health Matters Initiative Read More »
ASGCT 24th Annual Meeting Associate Members: Register for the Annual Meeting for Free We, here at the ASGCT 24th annual meeting, are excited for the conference this year! We want to express our gratitude to all our members for trusting ASGCT to add value to your career. Part of our mission is to be the
ASGCT 24th Annual Meeting Read More »
